Credits: None available.
SYNCHORONIZED CARE: Strategies to Improve Patient & Healthcare Outcomes in Heart failure
An online educational activity based on a CME Satellite Symposium presented at the 20h Annual Meeting of the Heart Failure Society of America in Orlando, FL.
This activity is intended for cardiovascular specialists, cardiovascular nurses and nurse practitioners, pharmacists, and other healthcare professionals caring for patients with heart failure.
Date of Release: December 1, 2016
Program End Date: November 30, 2017
Program Objectives:
Upon completion of this activity, participants will be able to:
Accreditation Statement
The Heart Failure Society of America is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The Heart Failure Society of America designates this enduring material for a maximum of 1 AMA PRA Category 1 Credits.™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Course Content - SYNCHORONIZED CARE: Strategies to Improve Patient & Healthcare Outcomes in Heart failure
Program Overview
Barry H. Greenberg, MD, FHFSA
Current Trends in Heart Failure Care
James L. Januzzi, Jr., MD
Current Evidence-Based Treatment. Options for Heart Failure
Javed Butler, MD, MPH, MBA
New Treatment Options and Synchronized Care
Barry H. Greenberg, MD, FHFSA
Panel Discussion
Faculty Panel
Disclosures
As a provider accredited by ACCME, HFSA ensures balance, independence, objectivity and scientific rigor in its educational activities. Course Directors, planning committee members, and speakers are required to disclose all relevant financial relationships. Faculty will also disclose off‐label or investigational uses of pharmaceuticals or devices discussed in their presentations. All potential conflicts have been resolved in accordance with ACCME guidelines for commercial support and content validation.
Speaker Disclosures:
Barry H. Greenberg, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for Bristol-Myers Squibb; Celladon Corporation; Johnson & Johnson; Mast Therapeutics, Inc.; Novartis Pharmaceuticals Corporation; Relypsa, Inc.; Teva Pharmaceutical Industries Ltd.; and Zensun USA, Inc.
Received Speaker Honoraria from Otsuka America Pharmaceutical, Inc.; Novartis Pharmaceuticals Corporation; and Relypsa, Inc.
Javed Butler, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for Amgen, Inc.; Bayer Corporation; Boehringer Ingelheim GmbH; CardioCell LLC.; Janssen Pharmaceuticals, Inc.; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Relypsa, Inc.; Stealth BioTherapeutics Inc.; Trevena Inc.; and ZS Pharma, Inc.
James L. Januzzi, Jr., MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for Novartis Pharmaceuticals Corporation and Roche
Received grants for clinical research from: Amgen, Inc.; Novartis Pharmaceuticals Corporation; Prevencio, Inc.; Roche; Siemens AG; and Singulex, Inc.
HFSA Planner / Reviewer Disclosures:
John Burnett, Jr., MD, has disclosed no relevant financial relationships.
Mona Fiuzat, PharmD, has disclosed no relevant financial relationships.
Gregg Fonarow, MD, has disclosed the following relevant financial relationships:
Received grants for clinical research from: National Institutes of Health (NIH).
Served as an advisor or consultant for: Amgen Inc.; Janssen Pharmaceuticals, Inc.; Medtronic; and Novartis Pharmaceuticals Corporation; St. Jude; and ZS Pharma
Kenneth Margulies, MD, has disclosed the following relevant financial relationships:
Received grants for clinical research from: CardioCell, LLC; Merk; Sharp and Dohme; and St. Lukes Hospital (Kansas City)
Served as an advisor or consultant for: GlaxoSmithKline; Merk; Janssen Pharmaceuticals, Inc.; and Sharp and Dohme.
Debra Moser, DNSc, RN, has disclosed no relevant financial relationships.
Marc Semigran, MD, has disclosed the following relevant financial relationships: Received grants for clinical research from: CVRx. Inc.; St. Jude Medical; and Novartis Pharmaceuticals Corporation. Served as an advisor or consultant for: Amgen Inc.; and Broadview.
David Whellan, MD, has disclosed no relevant financial relationships.
Jaime Abreu, MBA, has disclosed no relevant financial relationships.
MedEd Consulting, Inc. staff have disclosed no relevant financial relationships.
Commercial Support
Support for this enduring activity was provide through an independent educational grant from Amgen
Method of Participation and CME Certificate
The information provided in this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical/clinical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition.
To receive CME credit for this product, the participant must:
After successfully completing the post-test and evaluation, your CME certificate will be generated and immediately available for print.
Medium or Combination of Media Used
This enduring activity is available in these format offerings:
Heart Failure Society of America
6707 Democracy Blvd., Suite 925
Bethesda, MD 20817
Website: www.hfsa.org Email: info@hfsa.org
Customer Support
For support related to this site, please contact: {{$platformInstance.support.email}} or Toll Free: 877‐796‐1325
Privacy Policy
The website is provided by the Heart Failure Society of America (HFSA). HFSA only obtains personal information that you provide through your participation in this educational activity. Information is collected and retained solely for the purpose of identifying those who have participate and completed this activity. Your personal information will not be sold to any other entity.